- Home
- FUBO vs JANX Comparison
FUBO vs JANX Comparison
Compare FUBO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUBO
- JANX
- Stock Information
- Founded
- FUBO 2009
- JANX 2017
- Country
- FUBO United States
- JANX United States
- Employees
- FUBO N/A
- JANX N/A
- Industry
- FUBO Broadcasting
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- FUBO Industrials
- JANX Health Care
- Exchange
- FUBO Nasdaq
- JANX Nasdaq
- Market Cap
- FUBO 1.3B
- JANX 1.4B
- IPO Year
- FUBO 2020
- JANX 2021
- Fundamental
- Price
- FUBO $3.62
- JANX $24.97
- Analyst Decision
- FUBO Buy
- JANX Strong Buy
- Analyst Count
- FUBO 5
- JANX 8
- Target Price
- FUBO $5.35
- JANX $90.63
- AVG Volume (30 Days)
- FUBO 21.1M
- JANX 892.8K
- Earning Date
- FUBO 08-08-2025
- JANX 08-07-2025
- Dividend Yield
- FUBO N/A
- JANX N/A
- EPS Growth
- FUBO N/A
- JANX N/A
- EPS
- FUBO 0.26
- JANX N/A
- Revenue
- FUBO $1,625,738,000.00
- JANX $439,000.00
- Revenue This Year
- FUBO N/A
- JANX N/A
- Revenue Next Year
- FUBO $9.69
- JANX $1,470.83
- P/E Ratio
- FUBO $14.15
- JANX N/A
- Revenue Growth
- FUBO 6.65
- JANX N/A
- 52 Week Low
- FUBO $1.21
- JANX $21.97
- 52 Week High
- FUBO $6.45
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- FUBO 48.51
- JANX 52.30
- Support Level
- FUBO $3.50
- JANX $21.97
- Resistance Level
- FUBO $3.87
- JANX $25.93
- Average True Range (ATR)
- FUBO 0.30
- JANX 1.61
- MACD
- FUBO -0.03
- JANX 0.02
- Stochastic Oscillator
- FUBO 10.56
- JANX 60.84
About FUBO fuboTV Inc.
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.